Skip to main content
SpringerLink
Log in

V-domain Ig suppressor of T cell activation (VISTA) inhibition is a new approach to cancer therapy: a Bibliometric study

  • Review Article
  • Published:
Naunyn-Schmiedeberg's Archives of Pharmacology Aims and scope Submit manuscript

Abstract

V-domain Ig suppressor of T cell activation (VISTA) is a transmembrane protein that plays a crucial role in the regulation of antitumor immunity. Therapeutic intervention that inhibits the VISTA pathway constitutes a new approach in the treatment of cancer. The aim of the present study was to provide a bibliometric literature review of VISTA research in the field of cancer. Published articles on the topic were retrieved from the Web of Science Core Collection Database of Hassan II University from the beginning of the database to November 14, 2019. The articles were analyzed and a lot of information was available on the Web of Science, such as the number of citations, the names of the authors, country, publication year, Web of Science categories, and journal. A total of 76 papers (research and review articles) were retrieved from the Web of Science Core Collection Database to introduce VISTA research in cancer topic. All of the articles were published in English during the period between 2011 and 2019; the annual publications number has increased from 1 in 2011 to 22 in 2019. Cancer immunology immunotherapy journal, Cancer immunology research journal, and Cancer research journal, each one has published 3 articles (3.9% of the total publications), the impact factors of the journals ranged from 2.34 to 10.19. The author who has published high number of articles was Noelle RJ with 11 articles; according to the keyword co-occurrence, VISTA was the most frequent keyword with a frequency of 42.1%, followed by immune (36.8%). This is the first work that treats the application of bibliometric methods in VISTA research in the oncology field and represents an important bibliographic source for future studies on the role of VISTA in cancer and immunotherapy of cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  • Ahmed D, Albuarki J (2017) Review of the challenges of scientific research in the Arab world and its influence on inspiration driven economy. Int J Inspir Resilience Econ 1(1):28–34

    Google Scholar 

  • Arruebo M, Vilaboa N, Sáez-Gutierrez B, Lambea J, Tres A, Valladares M, González-Fernández Á (2011) Assessment of the evolution of cancer treatment therapies. Cancers (Basel). 3(3):3279–3330

    Article  CAS  Google Scholar 

  • Blando J, Sharma A, Higa MG, Zhao H, Vence L, Yadav SS, Kim J, Sepulveda AM, Sharp M, Maitra A, Wargo J, Tetzlaff M, Broaddus R, Katz MHG, Varadhachary GR, Overman M, Wang H, Yee C, Bernatchez C, Iacobuzio-Donahue C, Basu S, Allison JP, Sharma P (2019) Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer. Proc Natl Acad Sci U S A. 116(5):1692–1697

    Article  CAS  Google Scholar 

  • Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68(6):394–424

    Article  Google Scholar 

  • Ceeraz S, Nowak EC, Burns CM, Noelle RJ (2014) Immune checkpoint receptors in regulating immune reactivity in rheumatic disease. Arthritis Res Ther. 16:469

    Article  Google Scholar 

  • Christine B, Hans-Michael B, Sandra K, Christoph R (2017) The novel negative checkpoint regulator VISTA is expressed in gastric carcinoma and associated with PD-L1/PD-1: A future perspective for a combined gastric cancer therapy? ONCOIMMUNOLOGY. 6(4):e1293215

    Article  Google Scholar 

  • Deng J, Le Mercier I, Kuta A, Noelle RJ (2016) A New VISTA on combination therapy for negative checkpoint regulator blockade. J Immunother Cancer. 4:86

    Article  Google Scholar 

  • Flies DB, Higuchi T, Chen L (2015) Mechanistic assessment of PD-1H coinhibitory receptor-induced T cell tolerance to allogeneic antigens. J. Immunol. 194:5294–5304

    Article  CAS  Google Scholar 

  • Flies DB, Wang S, Xu H, Chen L (2011) Cutting edge: a monoclonal antibody specific for the programmed death-1 homolog prevents graft-versus-host disease in mouse models. J Immunol. 187:1537–1541

    Article  CAS  Google Scholar 

  • Gao J, Ward JF, Pettaway CA, Shi LZ, Subudhi SK, Vence LM, Zhao H, Chen J, Chen H, Efstathiou E, Troncoso P, Allison JP, Logothetis CJ, Wistuba II, Sepulveda MA, Sun J, Wargo J, Blando J, Sharma P (2017) VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer. Nat Med. 23(5):551–555

    Article  CAS  Google Scholar 

  • Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Abate D, et al (2019) Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2017: a systematic analysis for the global burden of disease study [published online ahead of print, 2019 Sep 27]. JAMA Oncol e192996

  • Kondo Y, Ohno T, Nishii N, Harada K, Yagita H, Azuma M (2016) Differential contribution of three immune checkpoint (VISTA, CTLA-4, PD-1) pathways to antitumor responses against squamous cell carcinoma. Oral Oncol 57:54–60

    Article  CAS  Google Scholar 

  • Le Mercier I, Chen W, Lines JL et al (2014) VISTA regulates the development of protective antitumor immunity. Cancer Res. 74(7):1933–1944. https://doi.org/10.1158/0008-5472.CAN-13-1506

    Article  CAS  PubMed  Google Scholar 

  • Le Mercier I, Lines JL, Noelle RJ (2015) Beyond CTLA-4 and PD-1, the generation Z of negative checkpoint regulators. Front Immunol. 6:418. https://doi.org/10.3389/fimmu.2015.00418

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Lines JL, Pantazi E, Mak J, Sempere LF, Wang L, O'Connell S, Ceeraz S, Suriawinata AA, Yan S, Ernstoff MS, Noelle R (2014) VISTA is an immune checkpoint molecule for human T cells. Cancer Res. 74:1924–1932

    Article  CAS  Google Scholar 

  • Liu M, Guo F (2018) Recent updates on cancer immunotherapy. Precis Clin Med. 1(2):65–74

    Article  Google Scholar 

  • Liu J, Xie X, Xuan C, Li T, Wang L, Teng L, Liu J (2018) High-density infiltration of v-domain immunoglobulin suppressor of T-cell activation up-regulated immune cells in human pancreatic cancer. Pancreas. 47(6):725–731

    Article  CAS  Google Scholar 

  • Marin-Acevedo JA, Dholaria B, Soyano AE, Knutson KL, Chumsri S, Lou Y (2018) Next generation of immune checkpoint therapy in cancer: new developments and challenges. J Hematol Oncol. 11(1):39

    Article  Google Scholar 

  • Mulati K, Hamanishi J, Matsumura N et al (2019) VISTA expressed in tumour cells regulates T cell function. Br J Cancer 120:115–127

    Article  CAS  Google Scholar 

  • Olsen J, Overvad K (1993) The concept of multifactorial etiology of cancer. Pharmacol Toxicol. 72(Suppl 1):33–38

    Article  Google Scholar 

  • Pritchard A (1969) Statistical bibliography or bibliometrics. J Doc. 25(4):348–349

    Google Scholar 

  • Rosenbaum SR, Knecht M, Mollaee M et al (2020) FOXD3 Regulates VISTA expression in melanoma. Cell Rep 30(2):510–524.e6

    Article  CAS  Google Scholar 

  • Villarroel-Espindola F, Yu X, Datar I, Mani N, Sanmamed M, Velcheti V, Syrigos K, Toki M, Zhao H, Chen L, Herbst RS, Schalper KA (2018) Spatially resolved and quantitative analysis of VISTA/PD-1H as a novel immunotherapy target in human non-small cell lung cancer. Clin Cancer Res. 24:1562–1573

    Article  CAS  Google Scholar 

  • Wang L, Rubinstein R, Lines JL, Wasiuk A, Ahonen C, Guo Y, Lu LF, Gondek D, Wang Y, Fava RA, Fiser A, Almo S, Noelle RJ (2011) VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses. J Exp Med. 208:577–592

    Article  CAS  Google Scholar 

  • White K, Robbins C (2017) Science and engineering publication output trends: 2014 shows rise of developing country output while developed countries dominate highly cited publications, N.C.f.S.a.E. statistics, editor. Arlington, VA: NSF

  • Wu L, Deng WW, Huang CF, Bu LL, Yu GT, Mao L, Zhang WF, Liu B, Sun ZJ (2017) Expression of VISTA correlated with immunosuppression and synergized with CD8 to predict survival in human oral squamous cell carcinoma. Cancer Immunol Immunother. 66(5):627–636

    Article  CAS  Google Scholar 

  • Xie S, Huang J, Qiao Q, Zang W, Hong S, Tan H, Dong C, Yang Z, Ni L (2018) Expression of the inhibitory B7 family molecule VISTA in human colorectal carcinoma tumors. Cancer Immunol Immunother. 67(11):1685–1694

    Article  CAS  Google Scholar 

  • Xu W, Hiếu T, Malarkannan S, Wang L (2018) The structure, expression, and multifaceted role of immune-checkpoint protein VISTA as a critical regulator of anti-tumor immunity, autoimmunity, and inflammation. Cell Mol Immunol. 15(5):438–446

    Article  CAS  Google Scholar 

  • Zhang H, Chen J (2018) Current status and future directions of cancer immunotherapy. J Cancer. 9(10):1773–1781

    Article  Google Scholar 

  • Zhu C (2018) Journal Impact Factor (JCR 2018)

Download references

Availability of data

The data presented in this article are available on Scopus database using the search query listed in the “Materials and methods” section.

Provenance and peer review

Not commissioned, externally peer-reviewed

Author information

Authors and Affiliations

  1. Laboratory of Cellular and Molecular Pathology, Faculty of Medicine and Pharmacy of Casablanca, University Hassan II, Casablanca, Morocco

    Oum Kaltoum Ait Boujmia

  2. Medical School of Casablanca, 19 Rue Tarik Ibnou Ziad, BP. 9154, Casablanca, Morocco

    Oum Kaltoum Ait Boujmia

Authors
  1. Oum Kaltoum Ait Boujmia
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

The author declares that all data were generated in-house and that no paper mill was used.

Corresponding author

Correspondence to Oum Kaltoum Ait Boujmia.

Ethics declarations

Consent to participate

Not applicable

Consent to publish

Not applicable

Conflict of interest

The author declares no competing interests.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ait Boujmia, O.K. V-domain Ig suppressor of T cell activation (VISTA) inhibition is a new approach to cancer therapy: a Bibliometric study. Naunyn-Schmiedeberg's Arch Pharmacol 394, 1057–1065 (2021). https://doi.org/10.1007/s00210-021-02068-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00210-021-02068-4

Keywords

Search

Navigation